FJY Stock Overview
Develops and commercializes generic and topical pharmaceuticals in Australia, Europe, the United States, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Acrux Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.035 |
| 52 Week High | AU$0.048 |
| 52 Week Low | AU$0.019 |
| Beta | 1.11 |
| 11 Month Change | -22.47% |
| 3 Month Change | 2.99% |
| 1 Year Change | 40.82% |
| 33 Year Change | -54.90% |
| 5 Year Change | -68.06% |
| Change since IPO | -75.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| FJY | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -11.5% | -7.0% | -0.1% |
| 1Y | 40.8% | -19.7% | 2.4% |
Return vs Industry: FJY exceeded the German Pharmaceuticals industry which returned -19.7% over the past year.
Return vs Market: FJY exceeded the German Market which returned 2.4% over the past year.
Price Volatility
| FJY volatility | |
|---|---|
| FJY Average Weekly Movement | 24.6% |
| Pharmaceuticals Industry Average Movement | 5.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: FJY's share price has been volatile over the past 3 months.
Volatility Over Time: FJY's weekly volatility (25%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | n/a | Michael Kotsanis | www.acrux.com.au |
Acrux Limited, together with its subsidiaries, develops and commercializes generic and topical pharmaceuticals in Australia, Europe, the United States, and internationally. The company offers testosterone solutions, such as oral tablets, buccal tablets, subcutaneous pellets, transdermal patches, injections, and topical gels for treatment of males. It also provides estradiol transdermal sprays for women under the Evamist and Lenzetto brand names for the treatment of flushes associated with menopause; and lidocaine and prilocaine cream, a generic version of EMLA cream, which is indicated as a topical anaesthetic for use on normal intact skin for local analgesia, and genital mucous membranes for superficial minor surgery and as a pre-treatment for infiltration anaesthesia.
Acrux Limited Fundamentals Summary
| FJY fundamental statistics | |
|---|---|
| Market cap | €11.91m |
| Earnings (TTM) | -€440.13k |
| Revenue (TTM) | €7.09m |
1.7x
P/S Ratio-27.1x
P/E RatioIs FJY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FJY income statement (TTM) | |
|---|---|
| Revenue | AU$11.42m |
| Cost of Revenue | AU$7.03m |
| Gross Profit | AU$4.39m |
| Other Expenses | AU$5.10m |
| Earnings | -AU$709.00k |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0024 |
| Gross Margin | 38.46% |
| Net Profit Margin | -6.21% |
| Debt/Equity Ratio | 0% |
How did FJY perform over the long term?
See historical performance and comparison